Forecast: (ATRA) for today October 27 & Weekly Forecast from 22 October to 28 October
Updated: October 27, 2023
Brief information about Atara Biotherapeutics, Inc.
Last trading day: 10/26/2023
Analyst forecast price: $22
52-week high/low: $20.04 / $2.98
Shares of Atara Biotherapeutics, Inc. are traded on the stock exchange under the ticker ATRA, marking their space in the competitive "Healthcare" sector. For stakeholders, tracking the dynamic price movement of ATRA is crucial for making informed investment decisions. In a market influenced by myriad factors, predicting the trajectory of these shares becomes both a challenge and a necessity. Predictive analytics and data-driven insights play a pivotal role in forecasting the performance of ATRA. The investors seeking up-to-date and accurate forecasts for Atara Biotherapeutics, Inc. shares can turn to resources like Allforecast.com. The website stands out as a reliable tool offering real-time predictions, ensuring that investors are equipped with current and anticipated stock trends. On Allforecast.com, users gain access to a comprehensive analysis and predictions specifically tailored for ATRA, spanning varied timeframes - from the next day's anticipations to weekly, monthly, and yearly forecasts. The platform’s real-time updating mechanism ensures that the forecasted data aligns with the ongoing market trends and economic shifts, offering users actionable insights to optimize their investment strategies. The forecasts integrate a mix of qualitative and quantitative analyses, sector-specific trends within "Healthcare", and broader market dynamics to present a holistic view of ATRA's expected performance. By leveraging such precise and timely data, investors can strategize their moves, balancing risks and opportunities associated with Atara Biotherapeutics, Inc.'s stocks. Navigating through the unpredictable terrains of the stock market requires actionable insights and timely data. Allforecast.com serves as a companion for investors eyeing ATRA, offering them a blend of accuracy and timeliness in predicting stock movements, aiding in informed and strategic investment choices.
Main Headquarters: Situated at 611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO, CA, US, this location serves as the primary hub for all corporate activities.
Atara Biotherapeutics's Current Market Value: As of our last update, it's pegged at $283 019 000, indicating its standing in the financial landscape.
Shares Overview: Currently, 93 406 000 shares of Atara Biotherapeutics are actively traded and held by the public.
Last year's EBITDA (Earnings Before Interest, Taxes, and Depreciation) for Atara Biotherapeutics stood at -341 649 984$. This figure provides insights into the company's operational profitability. On the other hand, a negative EBITDA hints at Atara Biotherapeutics's current challenges in achieving profitability.
In addition to fundamental factors, stocks are influenced by many other factors. For example, it is worth monitoring all global forecasts for Atara Biotherapeutics shares. Our service will help you with this, in which we collect all forecasts and build one consensus forecast from them.
Atara Biotherapeutics stock forecast
When considering an investment in Atara Biotherapeutics, prospective investors often seek insights on its long-term performance. Our platform consolidates the expert analyses and projections from renowned global analysts to offer a unified consensus forecast for 2023, 2024, 2025, 2026, and 2027.
With these forecasts at your disposal, you can address critical questions like:
What will be the price of one share of Atara Biotherapeutics in the subsequent years including 2023, 2024, 2025, 2026, and 2027?
What consensus have the analysts reached regarding the future performance of Atara Biotherapeutics stock?
Is Atara Biotherapeutics stock a viable option for both short-term and long-term investment?
Is it prudent to sell or hold Atara Biotherapeutics shares in 2023?
Is 2023 the opportune moment to buy Atara Biotherapeutics stock, or is patience a more viable strategy?
What are the anticipated entry and exit points for investing in Atara Biotherapeutics stock, according to expert forecasts?
It’s pivotal to remember that these forecasts are to be utilized as informational resources and not definitive investment advice. The final investment decision rests solely upon the investor, contingent on their risk tolerance, investment goals, and thorough analysis of Atara Biotherapeutics.
Insight into Our Forecasting Process
Our forecasting methodology encompasses the aggregation of public and expert data on Atara Biotherapeutics, coupled with a sophisticated algorithm that calculates a weighted average forecast while eliminating outliers. This ensures that our audience receives a refined and realistic projection of Atara Biotherapeutics stock’s future performance.
Atara Biotherapeutics Daily Share Price Forecast for One Month
Our team has meticulously gathered and analyzed forecasts from a diverse pool of analysts to present a consolidated average daily forecast for Atara Biotherapeutics shares over the upcoming month. It’s essential to bear in mind that short-term predictions can often be subject to significant volatility, influenced by a myriad of dynamic, real-time market factors.
As you scroll, you’ll discover a detailed graph illustrating the consensus forecast for Atara Biotherapeutics stocks over the next 30 days. The gray spectrum of the chart delineates the historical trajectory of the stock’s price, while the turquoise spectrum provides a visual representation of the anticipated price, inclusive of potential fluctuation ranges, offering insights into prospective market trends and stock behaviors.
In the dynamic world of stock trading, analysts and investors closely observe the projected highs and lows of Atara Biotherapeutics shares. Our integrated forecast predicts a peak price of $1.42 in the forthcoming 30 days, indicating the zenith of the stock's potential performance. An encouraging revelation, denoting an upside potential of 6.3% from the current standing.
On the flip side, the stock might plummet to a minimum of $1.26 within the same period. A decline of 6.36% signals caution, nudging investors towards a more conservative stance.
Consequently, a fluctuation corridor emerges, with the stock’s resistance at $1.42 and support at $1.26, indicating the oscillating nature of Atara Biotherapeutics’s stock over the one-month spectrum. These oscillations, while providing trading opportunities, should be navigated with adept knowledge and strategic foresight.
So, what’s the trajectory of Atara Biotherapeutics amidst these projections? The nuances of stock trading and investment are encapsulated in the constant ebb and flow of the market, influenced by intrinsic and extrinsic factors. Hence, a comprehensive, nuanced understanding of market dynamics, coupled with real-time analytics, emerges as the cornerstone for maximizing ROI and mitigating risks.
The evolution of Atara Biotherapeutics’s stock is akin to a narrative unfolding, shaped by myriad factors including market trends, economic indicators, and investor sentiment. Each fluctuation is a chapter of this narrative, offering insights, challenges, and opportunities to the discerning investor.
Evaluating the resilience of the support level is crucial in gauging the future trajectory of Atara Biotherapeutics shares. The anticipation is that the price will hover near the support level for 11 days. The support level at $1.26 appears to be resilient. A more pronounced fluctuation is anticipated, prompting a need for strategic reevaluation for investors.
It’s imperative to remember the innate unpredictability of the stock market. The actual future value of Atara Biotherapeutics shares is subject to variables beyond predictive analytics. Nonetheless, investors can expect the stock to oscillate within the defined optimistic and pessimistic target price brackets, offering both challenges and opportunities for strategic trading and investment.
| Date | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Oct 29 | 1.41 | 1.38 | 1.42 | 3.56 |
| Oct 30 | 1.41 | 1.39 | 1.42 | 2.01 |
| Oct 31 | 1.38 | 1.37 | 1.40 | 2.76 |
| Nov 01 | 1.37 | 1.34 | 1.40 | 4.11 |
| Nov 02 | 1.35 | 1.33 | 1.38 | 3.74 |
| Nov 03 | 1.35 | 1.33 | 1.38 | 3.45 |
| Nov 04 | 1.37 | 1.35 | 1.39 | 3.07 |
| Nov 05 | 1.37 | 1.35 | 1.40 | 3.73 |
| Nov 06 | 1.36 | 1.33 | 1.37 | 2.82 |
| Nov 07 | 1.33 | 1.30 | 1.36 | 4.26 |
| Nov 08 | 1.32 | 1.29 | 1.35 | 4.32 |
| Nov 09 | 1.34 | 1.33 | 1.36 | 1.87 |
| Nov 10 | 1.34 | 1.31 | 1.36 | 3.98 |
| Nov 11 | 1.32 | 1.29 | 1.34 | 3.84 |
| Nov 12 | 1.30 | 1.28 | 1.32 | 3.56 |
| Nov 13 | 1.29 | 1.27 | 1.31 | 2.46 |
| Nov 14 | 1.31 | 1.30 | 1.33 | 2.73 |
| Nov 15 | 1.33 | 1.32 | 1.34 | 1.79 |
| Nov 16 | 1.33 | 1.32 | 1.34 | 1.85 |
| Nov 17 | 1.30 | 1.29 | 1.31 | 2.03 |
| Nov 18 | 1.29 | 1.26 | 1.31 | 3.19 |
| Nov 19 | 1.31 | 1.28 | 1.33 | 4.21 |
| Nov 20 | 1.29 | 1.26 | 1.30 | 3.19 |
| Nov 21 | 1.32 | 1.30 | 1.35 | 3.68 |
| Nov 22 | 1.33 | 1.30 | 1.36 | 4.42 |
| Nov 23 | 1.32 | 1.30 | 1.35 | 3.84 |
| Nov 24 | 1.29 | 1.27 | 1.31 | 3.28 |
| Nov 25 | 1.30 | 1.28 | 1.32 | 2.62 |
| Nov 26 | 1.29 | 1.26 | 1.31 | 3.92 |
| Nov 27 | 1.27 | 1.26 | 1.29 | 2.70 |
Atara Biotherapeutics Stock Forecast 29 Oct.
Atara Biotherapeutics Stock Forecast 30 Oct.
Atara Biotherapeutics Stock Forecast 31 Oct.
Atara Biotherapeutics Stock Forecast 01 Nov.
Atara Biotherapeutics Stock Forecast 02 Nov.
Atara Biotherapeutics Stock Forecast 03 Nov.
Atara Biotherapeutics Stock Forecast 04 Nov.
Atara Biotherapeutics Stock Forecast 05 Nov.
Atara Biotherapeutics Stock Forecast 07 Nov.
Atara Biotherapeutics Stock Forecast 08 Nov.
Atara Biotherapeutics Stock Forecast 09 Nov.
Atara Biotherapeutics Stock Forecast 10 Nov.
Atara Biotherapeutics Stock Forecast 11 Nov.
Atara Biotherapeutics Stock Forecast 12 Nov.
Atara Biotherapeutics Stock Forecast 13 Nov.
Atara Biotherapeutics Stock Forecast 14 Nov.
Atara Biotherapeutics Stock Forecast 15 Nov.
Atara Biotherapeutics Stock Forecast 16 Nov.
Atara Biotherapeutics Stock Forecast 17 Nov.
Atara Biotherapeutics monthly stock forecast for 2023, 2024, 2025, 2026, 2027.
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Nov. | 1.36 | 1.25 | 1.43 | 12.27 |
| Dec. | 1.49 | 1.41 | 1.62 | 12.98 |
Diving into a more comprehensive insight, the monthly consensus forecast is an instrumental resource for investors eyeing Atara Biotherapeutics's performance metrics. These projections are meticulously curated, leveraging insights from renowned global analysts and offering a panoramic view of the anticipated stock behaviour for the current year and beyond.
In the mid-term analysis, forecasting accuracy enhances, attributed to the diminished influence of transient market fluctuations. For this year, the zenith of Atara Biotherapeutics share’s value is anticipated to touch $1.62, offering a robust metric for investment strategies, sans the extremes of varied agency forecasts.
On the contrary, the nadir projections settle at $1.25, delineating the lower threshold and offering a holistic perspective on the risk and return landscape.
Progressing further, we have extrapolated these analytical insights to generate consensus forecasts for subsequent years. The synthesized data, presented in intuitive tabular formats, offers investors, analysts, and enthusiasts a streamlined view into the future of Atara Biotherapeutics stocks.
Anticipated Trends: Atara Biotherapeutics (ATRA) Monthly Stock Trajectory for 2024
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 1.41 | 1.28 | 1.54 | 16.97 |
| Feb | 1.35 | 1.30 | 1.41 | 7.70 |
| Mar | 1.38 | 1.34 | 1.50 | 10.67 |
| Apr | 1.45 | 1.37 | 1.53 | 10.61 |
| May | 1.45 | 1.36 | 1.53 | 11.02 |
| Jun | 1.42 | 1.31 | 1.53 | 14.17 |
| Jul | 1.40 | 1.32 | 1.51 | 12.80 |
| Aug | 1.50 | 1.38 | 1.59 | 13.36 |
| Sep | 1.47 | 1.34 | 1.60 | 16.14 |
| Oct | 1.33 | 1.24 | 1.45 | 14.52 |
| Nov | 1.40 | 1.32 | 1.48 | 10.75 |
| Dec | 1.41 | 1.28 | 1.46 | 12.51 |
Atara Biotherapeutics (ATRA) Monthly Stock Prediction for 2025
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 1.40 | 1.30 | 1.43 | 9.13 |
| Feb | 1.53 | 1.42 | 1.57 | 9.95 |
| Mar | 1.68 | 1.59 | 1.84 | 13.48 |
| Apr | 1.74 | 1.65 | 1.83 | 9.50 |
| May | 1.85 | 1.70 | 1.96 | 13.18 |
| Jun | 1.87 | 1.78 | 1.99 | 10.39 |
| Jul | 1.82 | 1.68 | 1.86 | 9.82 |
| Aug | 1.89 | 1.81 | 1.94 | 6.43 |
| Sep | 1.94 | 1.82 | 2.03 | 10.43 |
| Oct | 2.13 | 1.94 | 2.20 | 11.86 |
| Nov | 2.28 | 2.16 | 2.43 | 11.24 |
| Dec | 2.19 | 2.01 | 2.31 | 12.87 |
Atara Biotherapeutics (ATRA) Monthly Stock Prediction for 2026
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 2.36 | 2.21 | 2.45 | 9.82 |
| Feb | 2.15 | 1.97 | 2.24 | 12.12 |
| Mar | 2.13 | 2.07 | 2.31 | 10.41 |
| Apr | 1.94 | 1.83 | 2.05 | 11.11 |
| May | 2.05 | 1.99 | 2.20 | 9.59 |
| Jun | 2.04 | 1.98 | 2.14 | 7.56 |
| Jul | 1.92 | 1.82 | 2.03 | 10.21 |
| Aug | 2.14 | 1.93 | 2.28 | 15.10 |
| Sep | 2.08 | 1.97 | 2.13 | 7.37 |
| Oct | 2.32 | 2.15 | 2.47 | 12.85 |
| Nov | 2.56 | 2.41 | 2.65 | 9.15 |
| Dec | 2.72 | 2.48 | 2.89 | 14.22 |
Atara Biotherapeutics (ATRA) Monthly Stock Prediction for 2027
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 2.98 | 2.86 | 3.08 | 7.21 |
| Feb | 3.06 | 2.80 | 3.23 | 13.50 |
| Mar | 3.20 | 2.93 | 3.31 | 11.58 |
| Apr | 3.13 | 3.04 | 3.29 | 7.74 |
| May | 3.06 | 2.87 | 3.18 | 9.68 |
| Jun | 3.40 | 3.22 | 3.57 | 9.61 |
| Jul | 3.50 | 3.40 | 3.66 | 7.23 |
| Aug | 3.88 | 3.76 | 4.05 | 7.24 |
| Sep | 3.84 | 3.56 | 4.14 | 14.01 |
| Oct | 3.80 | 3.65 | 4.08 | 10.61 |
| Nov | 3.92 | 3.76 | 4.12 | 8.58 |
| Dec | 4.04 | 3.83 | 4.36 | 12.22 |